Want to see AIDX full AI Analyst Report?
AIDX Stock Chart & Stats
$1.78
--
Market closed
$1.78
--
Day’s Range― - ―
52-Week Range$0.40 - $50.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$5.21M
Enterprise Value$37.71K
Total Cash (Recent Filing)$4.22M
Total Debt (Recent Filing)$925.49K
Price to Earnings (P/E)―
Beta2.38
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding12,251,198
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)-7.76
Price to Sales (P/S)72.96
P/FCF Ratio-0.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.04
Enterprise Value/Gross Profit0.20
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$5.00Price Target Upside180.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound And Improving Gross MarginA sharp revenue rebound in 2025 alongside a material gross margin improvement to about 29.6% signals the business can restore topline momentum and capture better unit economics. Sustained margin recovery supports long-term operating leverage if revenue growth is maintained.
Prior Profitable Operating HistoryHistorical profitability in 2021–2022 demonstrates the underlying lab-testing business can generate positive operating results under favorable conditions. This history suggests cost structure and revenue model are capable of profitability once demand and scale are restored.
Focused Diagnostic Laboratory Business ModelA specialized clinical laboratory model centered on diagnostic and blood-based assays creates recurring client relationships with healthcare providers and predictable service demand. Focused offerings enable operational refinement, protocol-driven delivery, and potential long-run margin improvements through scale.
Bears Say
Extreme Leverage And Negative EquityThe sharp deterioration to very high debt and negative shareholders' equity materially worsens solvency and refinancing risk. Over the medium term, heavy leverage constrains strategic flexibility, increases interest burden, and raises the probability of dilution or distressed financing needs.
Severe Cash BurnExtremely negative operating and free cash flow in 2025 indicates the company is consuming cash far faster than operations supply it. Persistent burn drives dependency on external capital, undermining financial stability and making long-term investment or execution riskier without credible cash-flow recovery.
Sustained Operating Losses And Volatile ResultsOngoing operating and net losses across multiple years reflect a cost structure that has not scaled with revenues. The volatility between prior profitable years and recent losses signals execution risk and uncertain margin sustainability, complicating planning and investor confidence in recovery.
20/20 Biolabs, Inc. News
AIDX FAQ
What was 20/20 Biolabs, Inc.’s price range in the past 12 months?
20/20 Biolabs, Inc. lowest stock price was $0.40 and its highest was $50.00 in the past 12 months.
What is 20/20 Biolabs, Inc.’s market cap?
20/20 Biolabs, Inc.’s market cap is $5.21M.
When is 20/20 Biolabs, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were 20/20 Biolabs, Inc.’s earnings last quarter?
Currently, no data Available
Is 20/20 Biolabs, Inc. overvalued?
According to Wall Street analysts 20/20 Biolabs, Inc.’s price is currently Undervalued.
Does 20/20 Biolabs, Inc. pay dividends?
20/20 Biolabs, Inc. does not currently pay dividends.
What is 20/20 Biolabs, Inc.’s EPS estimate?
20/20 Biolabs, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 20/20 Biolabs, Inc. have?
20/20 Biolabs, Inc. has 12,251,198 shares outstanding.
What happened to 20/20 Biolabs, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 20/20 Biolabs, Inc.?
Currently, no hedge funds are holding shares in AIDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
20/20 Biolabs, Inc.
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
AIDX Stock 12 Month Forecast
Average Price Target
$5.00
▲(180.90% Upside)
Biomerica
―
Co-Diagnostics
―
Lucid Diagnostics
―
Bluejay Diagnostics
―
Heart Test Laboratories, Inc.
―